IP Library Granted Patent US 8,586,314
Granted Patent B2
US 8,586,314 · App. 12/752,480 · Granted Nov 19, 2013

Peptide nucleic acid probes for detection, identification and/or quantitation of

Inventor: Henrik Stender (Gentofte, DK)
Assignee: AdvanDx, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,586,314
App. No.
12/752,480
Granted
Nov 19, 2013
Kind
B2
Abstract

Disclosed is a PNA probe that includes a nucleobase sequence suitable for the detection, identification and/or quantitation of Pseudomonas (sensu stricto). In one embodiment, the PNA probe is complementary to a target sequence of 23S rRNA or rDNA from all species of the genus Pseudomonas . The invention has a wide range of important uses including detecting Pseudomonas in a sample of interest.

Claims (16)

1. A PNA probe for the detection and/or quantitation of Pseudomonas (sensu stricto), wherein the probe consists of CCT ACC ACC TTA AAC (SEQ ID NO: 1).

2. A method for the detection and/or quantitation of Pseudomonas (sensu stricto) in a sample, said method comprising:

a) contacting the sample with a PNA probe consisting of CCT ACC ACC TTA AAC (SEQ ID NO: 1);

b) hybridizing the PNA probe to a target sequence of Pseudomonas (sensu stricto) in the sample; and

c) detecting the hybridization of the PNA probe to a target sequence as being indicative of presence and/or amount of Pseudomonas (sensu stricto) in the sample.

3. A method according to claim 2 , wherein the hybridization of the PNA probe to a target sequence takes place in-situ.

4. A method according to claim 2 , wherein the hybridization is by fluorescence in-situ hybridization.

5. A method according to claim 4 , wherein the hybridization does not involve the use of cross-linking reagents or enzymes prior to hybridization.

6. The method of claim 2 , wherein the method is used to detect a nucleic acid comprising a target sequence, wherein said nucleic acid has been synthesized or amplified in a reaction.

7. The method of claim 6 , wherein the nucleic acid synthesis or nucleic acid amplification reactions are selected from the group consisting of: Polymerase Chain Reaction (PCR), Ligase Chain Reaction (LCR), Strand Displacement Amplification (SDA), Transcription-Mediated Amplification (TMA), Rolling Circle Amplification (RCA) and Q beta replicase.

8. The method of claim 2 , wherein the method further comprises adding at least one blocking probe to reduce or eliminate any hybridization of the PNA probe to non-target sequence.

9. The method of claim 2 , wherein the target sequence is immobilized to a surface.

10. The method of claim 2 , wherein said PNA probe is immobilized to a surface.

11. The method of claim 10 , wherein said PNA probe is one component of an array.

12. The method of claim 2 , wherein the sample is a biological sample.

13. The method of claim 12 , wherein the biological sample is blood, urine, secretion, sweat, sputum, stool, mucous, or cultures thereof.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2021
From: MERCK GLOBAL HEALTH INNOVATION FUND, LLC
To: OPGEN, INC.; ADVANDX, INC.
Reel/Frame 055209/0242 →
SECURITY INTEREST Recorded Aug 17, 2015
From: OPGEN, INC.; ADVANDX, INC.
To: MERCK GLOBAL HEALTH INNOVATION FUND, LLC
Reel/Frame 036377/0129 →
Continuity (4)
Continuation 10821805 · Apr 8, 2004
Continuation In Part 10719979 · Nov 21, 2003
Provisional Application 60428554 · Nov 22, 2002
Related Publication 20100285987A1 · Nov 11, 2010